Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sponsor ID

20030123

Clinicaltrials.gov ID

NCT00094822

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

The purpose of this research study is to evaluate the safety and effectiveness of Neulasta® (pegfilgrastim) in reducing infection when given on the same day versus one day after the completion of chemotherapy (docetaxel and carboplatin) in patients with advanced or metastatic non-small cell lung cancer (NSCLC). This study is considered to be "investigational" because previous studies with Neulasta® used next day dosing and not same day dosing.

Additional Study Details

Phase

N/A

Product

pegfilgrastim

Type

Observational

Masking

N/A

Enrollment

Additional Study Details

Protocol Summary

Primary Outcome Measures

incidence of infection

Timeframe: during treatment

Secondary Outcome Measures

Not Available

Locations

No locations found.